Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment

NCT03672240 is registered in ClinicalTrials.gov with Asieris Pharmaceutical Technologies Co., Ltd. as lead sponsor.

NCT NCT03672240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03672240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment
Lead sponsor
Asieris Pharmaceutical Technologies Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2018
Completion date
June 30, 2020
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer (nmibc)